0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Drugs and Insomnia:  The Use of Medications to Promote Sleep

JAMA. 1984;251(18):2410-2414. doi:10.1001/jama.1984.03340420076032.
Text Size: A A A
Published online

ABSTRACT

The past decade has provided new developments and methodologies in sleep research, clinical practices, neuropharmacology, and psychiatric diagnoses. A taxonomy of sleep disorders has been advanced, and there are two newly marketed hypnotic drugs that are rapidly eliminated, as well as others under development. Use of a sleep-promoting medication is a decision that physicians and patients alike frequently encounter.

A recent national survey found that one third of the population reported some degree of insomnia, and half of this group—17% of the population—considered the insomnia serious. Half of the group with "serious insomnia" reported a high level of emotional distress. Only 10% of the subjects reporting "severe" insomnia received prescribed sleep-promoting medications; 5% used over-the-counter compounds. Surveys of primary care practice indicate that the bulk of hypnotic drug therapy is directed to women and the elderly with medical or mental disorders and only a very small proportion with a primary diagnosis of insomnia.

Since insomnia occurs in different diagnostic contexts and under a variety of circumstances, it is often difficult for the physician to know whether, when, and how to select and use hypnotics and other sleep-promoting medications. Yet, with the more extensive pharmacologic and clinical information now available, more effective day-to-day clinical decision making is possible.

As an aid to clinicians, the National Institute of Mental Health and Office of Medical Applications of Research of the National Institutes of Health convened a Consensus Development Conference on Nov 15 through 17, 1983, to address these questions and develop principles to facilitate diagnosis and treatment. After a day and a half of presentation of data by experts, a Consensus Panel consisting of psychiatrists, psychopharmacologists, biomedical researchers, epidemiologists, primary care physicians, and public representatives considered the evidence and agreed on answers to the following questions:

  1. Under what circumstances might a sleep-promoting medication be considered; in what types of sleep disturbances are sleep-promoting medications undesirable?

  2. What are the pharmacologic factors to be considered in the selection of sleep-promoting medications?

  3. What are the appropriate treatment strategies to be employed in using sleep-promoting medications on a short-term or long-term basis?

  4. What are the principal cautions and risks associated with prescribing these drugs; what special considerations should be applied in regard to medical status, age, concurrent drug use, or other factors?

  5. What research areas need further development?

Conclusions  Insomnia is a symptom or condition of heterogeneous origin. It signals the need for careful and systematic diagnostic inquiry. Primary medical, psychiatric, and other causes of insomnia should be identified and treated accordingly. Treatment of insomnia should start with the assessment and necessary correction of sleep hygiene and habits. Psychotherapy, behavioral approaches, and pharmacotherapy, alone or in combination, should be considered in the formulation of a comprehensive treatment plan. When pharmacotherapy is indicated, benzodiazepines are preferable. Patients should receive the smallest effective dose for the shortest clinically necessary period of time; this recommendation applies especially to the elderly. The choice of a specific drug should be based on its pharmacological properties in conjunction with the particular clinical situation and needs of the patient. Physicians should educate patients and monitor their conditions to evaluate and reduce the risks of dependence, side effects, and possible withdrawal difficulties. The treatment of insomnia will advance further with better understanding of the pathophysiologic features of sleep disorders, as well as with the improvement of sleep-promoting agents and techniques.

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();